What is Scout Bio?
Scout Bio is at the forefront of veterinary medicine, specializing in the creation of one-time gene therapies and monoclonal antibodies designed to treat major chronic health conditions in pets. Utilizing advanced Adeno-Associated Virus (AAV) vector technology, the company aims to achieve long-term expression of therapeutic proteins, thereby addressing critical unmet medical needs within the companion animal sector. Their strategic collaborations, notably with the University of Pennsylvania's Gene Therapy Program, bolster their capacity to advance the standard of care for pets afflicted by chronic diseases. Scout Bio's innovative approach targets pet owners and veterinary professionals seeking cutting-edge and effective treatment modalities for persistent animal health issues.
How much funding has Scout Bio raised?
Scout Bio has raised a total of $62.3M across 2 funding rounds:
Series A
$9.3M
Series B
$53M
Series A (2018): $9.3M with participation from Frazier Healthcare Partners
Series B (2021): $53M led by OrbiMed, Frazier Healthcare Partners, RiverVest Venture Partners, and Digitalis Ventures
Key Investors in Scout Bio
OrbiMed
OrbiMed is a specialized investment firm with deep expertise in the healthcare sector, managing capital across biopharmaceuticals, medical devices, and digital health. They support companies at various stages of development, from early-stage ventures to established organizations scaling solutions.
Frazier Healthcare Partners
Frazier Healthcare Partners is a venture capital firm focused on building life science companies. They invest in companies addressing significant unmet medical needs and aim to enhance patient lives through science, strategy, and innovation.
RiverVest Venture Partners
RiverVest Venture Partners is a venture capital firm dedicated to building life science companies that address significant unmet medical needs. They focus on enhancing patient lives and supporting entrepreneurs through scientific innovation and strategic investment.
What's next for Scout Bio?
The recent major strategic investment in Scout Bio signals a pivotal growth phase for the company, likely enabling accelerated development and commercialization of its gene therapy pipeline. This substantial backing from prominent healthcare investors suggests confidence in Scout Bio's technology and its potential to disrupt the veterinary pharmaceutical market. The company is poised to expand its research and development efforts, potentially forging new strategic partnerships and scaling its operations to meet the growing demand for advanced pet healthcare solutions. Future endeavors will likely focus on clinical validation, regulatory approvals, and market penetration, solidifying Scout Bio's position as a leader in innovative pet medicine.
See full Scout Bio company page
